These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9569080)

  • 61. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression.
    Chan TM; Li FK; Hao WK; Chan KW; Lui SL; Tang S; Lai KN
    Lupus; 1999; 8(7):545-51. PubMed ID: 10483033
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Intravenous cyclophosphamide pulse therapy on children with severe active lupus nephritis.
    Yan DC; Chou CC; Tsai MJ; Chiang BL; Tsau YK; Hsieh KH
    Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi; 1995; 36(3):203-9. PubMed ID: 7618472
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis.
    Aragon E; Resontoc LP; Chan YH; Lau YW; Tan PH; Loh HL; Ng KH; Yap HK
    Lupus; 2016 Apr; 25(4):399-406. PubMed ID: 26537422
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy of mizoribine in the treatment of systemic lupus erythematosus in children.
    Yoshidome K; Takei S; Imanaka H; Maeno N; Ohkawa T; Kawano Y
    Pediatr Int; 2004 Aug; 46(4):444-9. PubMed ID: 15310311
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.
    Chan TM; Li FK; Tang CS; Wong RW; Fang GX; Ji YL; Lau CS; Wong AK; Tong MK; Chan KW; Lai KN
    N Engl J Med; 2000 Oct; 343(16):1156-62. PubMed ID: 11036121
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical significance of necrosis in lupus nephritis.
    Makino H; Hayashi Y; Yamasaki Y; Shikata K; Kashihara N; Kira S; Ota Z
    Intern Med; 1994 Aug; 33(8):461-5. PubMed ID: 7803911
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis.
    Arends S; Berden JH; Grootscholten C; Derksen RH; Berger SP; de Sévaux RG; Voskuyl AE; Bijl M;
    Neth J Med; 2014 Nov; 72(9):481-90. PubMed ID: 25431394
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Successful treatment of early intervention with tacrolimus for a patient with lupus nephritis III+V].
    Yoshida S; Kotani T; Takeuchi T; Isoda K; Hata K; Watanabe K; Shoda T; Inoue T; Makino S; Hanafusa T
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Dec; 31(6):460-4. PubMed ID: 19122377
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Renal involvement in systemic lupus erythematosus in Pakistan.
    Rabbani MA; Tahir MH; Siddiqui BK; Ahmad B; Shamim A; Shah SM; Ahmad A
    J Pak Med Assoc; 2005 Aug; 55(8):328-32. PubMed ID: 16164159
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.
    Rovin BH; Furie R; Latinis K; Looney RJ; Fervenza FC; Sanchez-Guerrero J; Maciuca R; Zhang D; Garg JP; Brunetta P; Appel G;
    Arthritis Rheum; 2012 Apr; 64(4):1215-26. PubMed ID: 22231479
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Longterm Data on Sirolimus Treatment in Patients with Lupus Nephritis.
    Yap DYH; Tang C; Chan GCW; Kwan LPY; Ma MKM; Mok MMY; Chan TM
    J Rheumatol; 2018 Dec; 45(12):1663-1670. PubMed ID: 30275264
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.
    Dunn CJ; Wagstaff AJ; Perry CM; Plosker GL; Goa KL
    Drugs; 2001; 61(13):1957-2016. PubMed ID: 11708766
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Interstitial lupus nephritis].
    Gerl A; Samtleben W; Helmchen U; Bartl R; Köhler JA; Wilmanns W
    Dtsch Med Wochenschr; 1992 May; 117(20):782-6. PubMed ID: 1587209
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis.
    F L; Y T; X P; L W; H W; Z S; H Z; Z H;
    Lupus; 2008 Jul; 17(7):622-9. PubMed ID: 18625634
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial.
    Grootscholten C; Ligtenberg G; Hagen EC; van den Wall Bake AW; de Glas-Vos JW; Bijl M; Assmann KJ; Bruijn JA; Weening JJ; van Houwelingen HC; Derksen RH; Berden JH;
    Kidney Int; 2006 Aug; 70(4):732-42. PubMed ID: 16820790
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study.
    ACCESS Trial Group
    Arthritis Rheumatol; 2014 Nov; 66(11):3096-104. PubMed ID: 25403681
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Sandimmun-Neoral--a new quality of life for patients with severe systemic juvenile rheumatoid arthritis].
    Alekseeva EI; Shakhbazian IE
    Ter Arkh; 1999; 71(5):26-9. PubMed ID: 10399226
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Immunosuppressive therapy in lupus nephritis.
    D'Cruz D; Cuadrado MJ; Mujic F; Tungekar MF; Taub N; Lloyd M; Khamashta MA; Hughes GR
    Clin Exp Rheumatol; 1997; 15(3):275-82. PubMed ID: 9177922
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.